Early genetic risk clues for Alzheimer’s and related dementias
Official title: Leveraging high-throughput functional data for assessment of Alzheimer's risk
Funded at Constantiam Biosciences INC. · NIH-11406172 · Data updated 2026-11-12
A focused project to help people understand how their genes might signal risk for Alzheimer’s and similar dementias earlier in life.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Constantiam Biosciences INC. NIH-funded |
| Lab location | 1 site (Katy, United States) |
| Project start | September 24, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,252,240 |
| NIH project number | 2R44AG084431-02 |
| Project ID | NIH-11406172 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants are individuals who have a family history or genetic findings related to Alzheimer’s or ADRD and are seeking clearer risk information.
✕Less likely to help
People without relevant genetic results or those not considering genetic risk information may not benefit.
What this research studies
This project uses a cutting-edge computational platform to interpret genetic variants linked to Alzheimer’s and related dementias. It aims to turn thousands of gene variants into actionable risk information using high-throughput functional data. The team will combine MAVEs data with established guidelines to improve how variants are classified and used in clinical decisions. The work could lead to earlier identification of individuals at higher risk and inform personalized prevention strategies.
Why it matters
Potential benefit: If successful, this could enable earlier and clearer risk flags for Alzheimer’s-related conditions, informing prevention or monitoring plans.
How similar studies have gone: Prior MAVEs data have helped reclassify a substantial portion of variants, suggesting potential for meaningful impact in this area.
Where this research is happening
-
Constantiam Biosciences INC.
Katy, United States Active
Researchers
- Principal investigator: Schafer, Nicholas P — Constantiam Biosciences INC.
- Study coordinator: Schafer, Nicholas P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.